











































Vaccination and allergy: EAACI position paper, practical aspects
Citation for published version:
Nilsson, L, Brockow, K, Alm, J, Cardona, V, Caubet, J, Gomes, E, Jenmalm, MC, Lau, S, Netterlid, E,
Schwarze, J, Sheikh, A, Storsaeter, J, Skevaki, C, Terreehorst, I & Zanoni, G 2017, 'Vaccination and
allergy: EAACI position paper, practical aspects', Pediatric Allergy and Immunology.
https://doi.org/10.1111/pai.12762
Digital Object Identifier (DOI):
10.1111/pai.12762
Link:




Pediatric Allergy and Immunology
Publisher Rights Statement:
This is the author's peer reviewed manuscript as accepted for publication.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.










This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/pai.12762 
This article is protected by copyright. All rights reserved. 
DR LENNART JAN NILSSON (Orcid ID : 0000-0002-5680-6367) 
DR MARIA CHRISTINA JENMALM (Orcid ID : 0000-0002-2117-5366) 
 
 
Article type      : Review 
 
 
 Vaccination and allergy:  
EAACI position paper, practical aspects 
 
Lennart Nilsson1, Knut Brockow2, Johan Alm3, Victoria Cardona4, Jean-Christoph 
Caubet5, Eva Gomes6, Maria C. Jenmalm7, Susanne Lau8, Eva Netterlid9, Jürgen 
Schwarze10, Aziz Sheikh11, Jann Storsaeter12, Chrysanthi Skevaki13, Ingrid 
Terreehorst14, Giovanna Zanoni15 
1Allergy Center, University Hospital, Linköping, Sweden; 2 Department of Dermatology and 
Allergy Biederstein, Technical University Munich, Germany; 3 Sachs´ Children and Youth 
Hospital, Stockholm, Sweden; 4Allergy Section, Department of Internal Medicine, Hospital 
Universitari Vall d'Hebron, Barcelona, Spain, 5University of Geneva, Division of Paediatrics, 
Genève, GE, Switzerland, 6CHP, Porto, Portugal; 7Unit of Autoimmunity and Immune 
Regulation, Department of Clinical and Experimental Medicine, Linköping University, 
Linköping, Sweden; 8Pediatric Pneumology and Immunology, Charité Universitätsmedizin, 
Berlin, Germany;  9Department of Occupational and Environmental Dermatology, Lund 
University, Malmö, Sweden and The Public Health Agency of Sweden; 10Child Life & Health 
and MRC-Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK; 
11Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and 
Informatics. The University of Edinburgh, UK; 12Norwegian Institute of Public Health; 
13Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps 
University Marburg, University Hospital Giessen and Marburg GmbH, Marburg, Germany, 
14AMC, Dept ENT, the Netherlands; 15Immunology Unit, University Hospital, Verona, Italy  
Dedicated to Christoph Grüber and Isil Barlan 










This article is protected by copyright. All rights reserved. 
Title: 57 characters, Short title “Vaccination and allergy: EAACI position paper” 40 characters 
Conflict of interest: See COI for the authors, respectively 
Correspondence: Lennart Nilsson, Allergy Centre, University Hospital, Linköping, Sweden, 
+46 (0)10 - 103 4781, fax +46 (0)10-1034773, Lennart.J.Nilsson@Regionostergotland.se 
Words: 5239. Abstract 184 References: 83. Figures/tables: 10. 
 
Abstract 
Immunization is highly effective in preventing infectious diseases and therefore an indispensable public health 
measure. Allergic patients deserve access to the same publicly recommended immunizations as nonallergic 
patients unless risks associated with vaccination outweigh the gains. 
Whereas the number of reported possible allergic reactions to vaccines is high, confirmed vaccine-triggered 
allergic reactions are rare. Anaphylaxis following vaccination is rare, affecting less than 1/100,000, but can 
occur in any patient. Some patient groups, notably those with a previous allergic reaction to a vaccine or its 
components, are at heightened risk of allergic reaction and require special precautions. Allergic reactions, 
however, may occur in patients without known risk factors and cannot be predicted by currently available 
tools. Unwarranted fear and uncertainty can result in incomplete vaccination coverage for children and adults 
with or without allergy. 
In addition to concerns about an allergic reaction to the vaccine itself, there is fear that routine childhood 
immunization may promote the development of allergic sensitization and disease. Thus, although there is no 




This position paper provides expert advice on how to prevent and manage allergic reactions to vaccines 
against infectious diseases, and immunization in relation to the development of allergic diseases. Because 
systemic reactions can cause greater harm than local reactions, this paper focuses on the former.  
 
Methods 
Evidence and recommendations provided are based on currently available published data. In January 2013, 
articles in English, German, and Italian with data on hypersensitivity reactions to vaccines were identified by 
searching the Medline (National Library of Medicine) database. Additional articles were found through the 
reference lists of the identified articles, textbooks, publications of national registries or organizations, existing 
guideline articles, and a Medline search update covering January 2013-September 2016. Relevant articles were 
identified on the basis of title and abstract, retrieved and analysed. Evidence was discussed, and statements 
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I. Basic information 
I A. Allergic reactions to vaccines.  
Statement: Allergic reactions to vaccines are rare, mostly directed to additives. Knowledge of all ingredients is 
of importance when vaccinating an allergic individual. 
Documented allergic reactions have been reported for all vaccines but account only for a minority of all 
adverse events following immunization (AEFI, abbreviations; see also Table 1). In addition to microbial 
antigens, vaccines may include stabilizers, adjuvants, preservatives, and residual contaminants from the 
production process. (1, 2, http://www.vaccinesafety.edu/components.htm and 
http://www.cdc.gov/vaccines/pubs/pinkbook/appendix/index.html). Although microbial antigens rarely cause 
allergic reactions, they have been described in recent papers for anaphylaxis associated with influenza vaccine 
and for a mutant diphtheria toxin (CRM197) in pneumococcal conjugated vaccine (PCV) (3, 4). Knowledge of all 
the ingredients in a vaccine is crucial to identifying the culprit allergen. The principal allergens in vaccines are 
listed below. 
 
Gelatine, a vaccine stabilizer of bovine or porcine origin, has been reported to be responsible for anaphylaxis 
to some brands of measles, mumps, and rubella (MMR) and varicella vaccines, and also earlier in Japanese 
encephalitis and influenza vaccines.  
Residual ovalbumin from hen’s egg can be present in yellow fever (YF), influenza, MMR, tick-borne 
encephalitis (TBE) and some rabies vaccines in various concentrations (Figure 1). Chicken protein in YF vaccine 
has been reported to be a potential severe problem in chicken-allergic recipients. Very low concentration of 
cow’s milk proteins may be present in some brands of diphtheria, tetanus and pertussis (DTP) vaccines, and 
oral polio vaccine (OPV) (5).  
Thiomersal, aluminium, and phenoxyethanol can cause local reactions (mostly delayed-type hypersensitivity 
such as contact allergy and maculopapular rash), but have not been reported as a cause of proven anaphylaxis. 
Nowadays, thiomersal is rarely used as a preservative in vaccines, and its clinical importance as an allergen is 
doubtful (6). Local reactions can nevertheless be more frequent among sensitized recipients (7). 
Formaldehyde is still used in vaccine preparation (8), but no IgE-mediated reactions to formaldehyde have 
been recently described.  
Trace amounts of antimicrobials could theoretically cause anaphylaxis in sensitized patients; however, few 
reports are found in the literature. Although the association of neomycin sensitization and IgE-mediated 
allergic reactions to vaccines is poorly supported by the literature, a history of anaphylaxis to neomycin is 
considered a contraindication for immunization with vaccines containing neomycin (9). Contact dermatitis with 
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Vaccine vial stoppers or syringe plungers may contain natural latex rubber and pose a theoretical risk to latex-
allergic patients (10). Incidence is, however low; only one report of an anaphylactic reaction in a latex-allergic 
patient was attributed to rubber in the stopper (11) of an Hepatitis B (HB) vaccine. Human papillomavirus 
vaccines (HPV) may contain residual yeast protein (Saccharomyces cerevisiae) from the production process. 
Rarely, an immediate reaction can happen after vaccination in yeast-allergic patients (12). Yeast is also used in 
the production of the carrier CRM197, and could theoretically be contained in PCV-13 and some 
meningococcal and oral typhoid vaccines. (1). Dextran has been implicated in allergic reactions to some 
vaccines that have been withdrawn from the market (1). Alpha-gal anaphylaxis minutes after 
immunisation with zoster vaccine (OKA VZV) has recently been suggested in a patient with a 
documented history of red meat allergy. It has been postulated that the patient has reacted to 
alpha-gal from porcine gelatin or bovine calf serum in the vaccine (13). 
I B. Immune response to vaccines in relation to allergy 
Statement: Determination of vaccine antigen-specific IgE is not recommended in the work-up of allergic 
reactions to vaccines, because IgE production can be part of the normal vaccine immune response and it is 
mainly not commercially available. 
Specific IgE response to vaccine antigens can frequently be observed alongside IgG responses (14). After 
primary immunization, about 50% of infants have detectable IgE against D and T toxoids [14]; after booster, 
more than 90% of vaccines have detectable IgE against the vaccine antigens [15]. The IgE response to vaccine 
antigens, mediated by a Th2-type immune response, seems more pronounced among atopic individuals [14]. It 
has therefore been hypothesized that immunization of atopic children may be associated with clinical vaccine 
allergy. However, no relevant clinical allergic reaction to microbial antigens in vaccines has been reported 
before two recent papers, see 1A (3, 4). In young children, Th1-/IFN-associated and Th2-associated gene 
networks coexist in an apparent state of dynamic equilibrium, but atopic individuals have Th2-dominant 
allergen-specific responses, and their Th1/IFN networks are disrupted and down-regulated (16). Therefore, the 
optimal immunogenicity/reactivity balance of new vaccines will have to be specifically defined in this 
population. 
 
I C. Systemic and local reactions  
Statement: Anaphylaxis following vaccination is rare and has to be distinguished from vasovagal reaction. 
Local reactions are common and mainly due to non-allergic immune reaction. 
Classification of hypersensitivity reactions to vaccines is challenging as the underlying mechanisms are poorly 
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extent, severity and timing of the reaction (17). In this paper, reactions after vaccination are categorized as 
systemic and local reactions according to WHO (18).  
 
Systemic reactions 
Among AEFI, systemic severe allergic reactions are rare but important. Anaphylaxis is an acute severe, 
potentially life-threatening emergency (19), Table 2. Symptoms usually start within the first hour after 
immunization (17). Reactions occurring more than two hours after exposure have been described, but are 
uncommon, and the causal relationship is unclear (20). The incidence of anaphylactic reactions to certain 
vaccines is listed in Table 3. In typical cases with multi-organ involvement and objectively measurable signs in 
the four organ systems (skin, gastrointestinal tract, respiratory tract and cardiovascular system), diagnosis can 
be easy and certain. In other cases, diagnosis may be difficult, and anaphylaxis has to be differentiated from 
vasovagal reaction after immunization, Table 4. 
 
Anaphylactic reactions can be IgE-mediated or non-IgE-mediated; these can be difficult to differentiate 
clinically.  
Non-allergic systemic reactions should be distinguished from systemic IgE-mediated reactions. Fever and 
nonspecific systemic symptoms, such as skin rash, irritability, malaise, diarrhoea, headache, muscle pains and 
syncope are the most common systemic events after vaccination. Skin rashes, delayed urticaria and/or 
angioedema or maculopapular skin rash often occur a few hours after vaccine administration. Nonspecific 
activation of the immune system and nonspecific degranulation of mast cells may be the cause (21).  
Local reactions 
Local reactions include pain, redness and/or swelling at injection site. Mild local reactions are attributed to 
nonspecific inflammation due to the injection itself and injection of foreign materials. Large local reactions are 
less common and usually occur within 24-72 hours after vaccine administration . However, after a fifth dose of 
DTaP vaccine in 4-5 year-olds, about 1/4 of the children will get a large local reaction, usually well tolerated 
and resolving within 1-2 weeks (22). Typical large local reactions and chronic subcutaneous nodules with 
itching and eczema are considered type IV reactions. Local reactions could also be Arthus type, i.e. type III 
hypersensitivity. For these, the administration technique is important; deeper injection is associated with a 
lower rate of local reactions, especially in children younger than 3 years (23). Injection in the arm is associated 
with higher incidence of reactions than injection in the thigh (24). Traces of antibiotics, thiomersal and 
formaldehyde can contribute to local reactions. The incidence of local reactions for certain vaccines is shown 
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I D. Possible development of allergy by immunization 
Statement: Routine childhood immunization does not promote the development of allergic sensitization to 
common inhalant or food allergens or the development of allergic disease.  
Immunizations have been widely suspected of promoting the development of allergies, with related concerns 
contributing to delayed or incomplete immunization (25). 
Epidemiological studies have addressed a possible effect of immunization on allergy development in general. 
However, immunizations had no effect on allergic disease in several studies (26, 27). Higher cumulative vaccine 
antigen doses were associated with less allergic sensitization, allergic disease (28) and less severe infant 
eczema (29). In concordance, regional immunization rates were inversely associated with allergic disease (30). 
Pertussis immunization has been suspected as pro-allergic because P toxin, included in cellular and acellular 
vaccines, can enhance IgE formation. However, data from a randomized intervention trial failed to show an 
increased risk of allergic sensitization or allergic disease up to 7 years of age (31). In a large ecological study, 
there was no increased risk of requiring asthma medication in adolescents whether they had had P vaccination 
in infancy or not (32). 
Lower rates of allergic symptoms and allergic sensitization have been found among children with measles, but 
no association was found between measles vaccination and allergic symptoms (33). DT immunization was 
associated with asthma in one study (34), but not in others. Importantly, several further studies could not find 
any effect of MMR (28, 35), Haemophilus influenzae type b (36) or DTP (27) vaccinations on allergic 
sensitization or allergic disease. Mycobacterial lipoproteins elicit particularly strong Th1 responses. 
Consequently, it has been suggested that BCG vaccine administered in infancy might protect against the 
development of Th2-mediated allergic disease. A systematic review and meta-analysis (37) suggested that BCG 
vaccination is unlikely to be effective in preventing allergic sensitization or eczema, but might offer transient 
benefits against developing asthma.  
 
Topic II Specific vaccines and adverse events 
Topics II A. Diphtheria, tetanus, pertussis vaccines 
True allergic or immediate hypersensitivity reactions to routine vaccines are rare, estimated as 2 per million 
doses for DTaP (20). In Japan (1994-2004) the total incidence of anaphylaxis was 0.95 per million doses of 
DTaP, but the authors were unable to identify a causal relationship to any vaccine component (38). Neither 
skin prick tests (SPT) nor specific IgE analyses could predict these reactions.  
Specific IgE antibodies to D, T and P vaccines are common after booster doses if primary vaccination was with 
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Elevated P toxin IgE levels are associated with local reactions (40). As the adjuvant effect of aluminium on IgE 
production is well known, controversy exists regarding the extent to which the toxoids cause the local 
reactions (22).  
 
Casein, a cow’s milk protein, has been implicated as a cause of anaphylaxis to DTP-containing vaccines in 
children with severe milk allergy and high specific milk IgE levels (41). Whereas these data need to be 
confirmed, trace amounts of casein have been demonstrated in some brands of DTaP or dTaP-containing 
vaccines prepared in a medium derived from cow’s milk protein. However, it is important to recognize that 
most patients with even severe milk allergy tolerate childhood vaccines, so no changes to vaccine 
recommendations have resulted from these case reports (42). 
II B. Influenza vaccination 
Vaccines for influenza prevention include the trivalent and quadrivalent inactivated influenza vaccines (IIVs), 
recombinant subunit vaccine (RIV), and live attenuated three and quadrivalent influenza vaccines (LAIVs). 
According to the Centers for Disease Control and Prevention (CDC) and WHO, individuals from six months of 
age should be vaccinated against seasonal influenza 
[http://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm?s_cid=rr6505a1_w; August 26, 2016].  
IIVs have generally been found to be safe for adults and children with asthma [43, 44], including those with 
severe disease [44]. Medically significant wheezing was increased in children 6–23 months of age who had 
received LAIVs but not in children 2–5 years of age [45]. Moreover, a recent Cochrane review did not show any 
significant increase in acute asthma exacerbations immediately following IIVs in adults or children older than 3 
years of age [46]. In addition, data support the safety and efficacy of LAIVs among children aged 2-17 years 
with mild to moderate asthma or with a history of wheezing [47], but data regarding individuals with severe 
asthma/active wheezing are limited.  
Recent studies provide robust evidence that IIVs with low ovalbumin content (< 0.12 µg/mL), can be 
administered safely in egg allergic patients, even in those with severe reactions (48 - 50). Data regarding the 
safety of LAIVs in egg allergy is emerging. The upper ovalbumin content of LAIVs is, reported on the package 
insert, 0.24 µg per 0.2 mL dose, but independent laboratories found it to be very low, between 0.00013 and 
0.0017 µg per 0.2 mL dose (17). The ovalbumin content is published prior to the influenza season each year 
(https://www.gov.uk/government/collections/vaccine-update). The recent SNIFFLE studies combined found no 
systemic vaccine reactions and only 17 (1.6%) mild self-limiting reactions in 1,242 LAIV doses given to 1,061 
egg-allergic children, including 335 with previous anaphylaxis to egg (49, 50). Based on these results, UK 
immunization recommendations no longer consider egg allergy a contraindication to LAIV, unless a child has 
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II C. MMR vaccine 
MMR vaccination has been considered a problem in egg-allergic children because the attenuated viruses are 
cultured in hen’s embryonic fibroblasts, and the vaccines could contain traces of ovalbumin. However, several 
studies revealed that MMR vaccination is safe in infants and children with egg allergy (52). There are, however, 
reports of allergic reactions to gelatine (53).  
Recent data confirm that infants and children allergic to hen’s egg can be vaccinated in GP settings and do not 
have to be referred to specialized centres. A review of the Irish paediatric emergency department vaccination 
programme for patients at risk of allergy/anaphylaxis analysed the clinical outcome of 374 children referred 
due to a history of allergy or anaphylaxis after 446 vaccine doses, including 310 (69.5%) MMR doses, were 
administered to 374 patients. Only six patients (1.3%) experienced a minor immediate reaction to a 
vaccination (54). In the Danish Childhood Vaccination Programme, 32 patients with sensitization to hen’s egg 
displayed no reaction to MMR vaccine (Priorix®) (55). 
The British Society for Allergy and Clinical Immunology (BSACI) guidelines for the management of egg allergy 
recommend that children with egg allergy should receive routine MMR vaccination in primary care (56).  
 
II D. Pneumococcal and meningococcal vaccines 
There are no contraindications to pneumococcal or meningococcal vaccines for patients with allergy except for 
those with other known hypersensitivity to vaccine components including D (or CRM 197) or T toxoids present 
as carriers in conjugated vaccines, or previous severe reaction to the vaccine.  
II E. BCG vaccine 
Most adverse reactions after BCG vaccination are infectious. Hypersensitivity reactions are mostly mild 
injection site reactions and lymphadenitis, whereas systemic reactions, such as the immune reconstitution 
inflammatory syndrome, are rare (57). 
 II F. Polio vaccination  
A theoretical risk of hypersensitivity reactions exists due to trace amounts of streptomycin, neomycin and 
polymyxin B in both injectable and oral polio vaccine. The latter may also contain cow's milk proteins (5) (see I 
A). Confirmed anaphylaxis is extremely rare. Data from the UK, Canada and the US indicate rates of 0.65-3 
anaphylaxis events per million doses of vaccine administered (58). 
II G. Hepatitis B vaccination 
Hepatitis B (HB) vaccines are manufactured in yeast cells, and residual Saccharomyces cerevisiae antigens can 
be present in the product. Anaphylaxis in children with HB vaccine has been rarely reported; it has been 
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recipient with the causative agent most likely being latex (11). The package components have been changed, 
and latex is currently not present.  
II H. Yellow fever vaccine 
Demand for the vaccine is increasing, with more than 60 million doses administered annually (59).  
The YF vaccine Stamaril (UK) contains 0.13 to 0.61 ug/ml of egg protein (60) and YF-VAX contains 2.43 to 4.42 
ug/ml of egg protein (59), used in US. Compared to the recommendations for egg protein in TIV, egg protein in 
Stamaril is not high. However, no large studies about egg allergy in YF vaccines exist. Anaphylaxis risk from YF 
vaccine ranges from 0.42 to 1.8/100,000 doses (60). With the low ovalbumin content in the present YF vaccine, 
desensitization will probably not be necessary henceforth. However, egg allergic persons should be evaluated 
by an allergist before YF vaccination (See IIIC). 
II I. HPV vaccine 
IgE mediated anaphylaxis to quadrivalent HPV vaccine is rare, 2.6/100,000 (61). An expert panel classifying 
suspected cases using the Brighton Collaboration (BC) case definition of anaphylaxis found eight cases. The 
panel rejected the possibility that these could have been vasovagal episodes or somatic conversion disorder 
misdiagnosed as anaphylaxis. The anaphylaxis rate was higher than in previous vaccination programs. 
However, there was no anaphylactic shock.  
Allergenicity of the vaccine is biologically plausible for HPV virus-like particles, which are highly immunogenic 
when injected (62). Any residual amounts of yeast proteins might cause allergic reactions (12); the 
quadrivalent vaccine also contains polysorbate 80 as a stabilizer, which might trigger anaphylaxis (63).  
II J. TBE – tick-borne encephalitis vaccine 
In the 1990s, the TBE vaccine (Encepur, Chiron Vaccines) caused an immediate allergic reaction in 
approximately 1/ 50,000 doses and was modified in 1998. The stabilizer polygeline (a gelatine) was replaced 
with human serum albumin, and the immediate reactions decreased to 0.08-0.24/100,000 doses (64).  
 
III. Diagnostic aspects of severe reactions 
In the setting of vaccination reactions, different definitions and grading systems for anaphylaxis have been 
proposed. Our group prefers the case definition of anaphylaxis established at an NIH consensus conference 
and subsequently endorsed by WAO and EAACI (Table 2, NIH criteria for anaphylaxis). The definition is widely 
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III A. Diagnostic tests of severe reactions  
Serum mast cell tryptase (MCT) levels have been used as a marker of anaphylaxis [65], although its predictive 
value for vaccine-associated anaphylaxis has not been formally established. We recommend MCT level 
determined within 2 hours after a systemic vaccine reaction, as well as serum baseline tryptase evaluated at 
least 48 hours afterwards. A significant increase in MCT level from baseline is a strong indicator of a systemic 
mast-cell-mediated hypersensitivity reaction.  
If a patient has had a suspected allergic reaction to a vaccine, identification of the culprit allergen is important, 
because it may permit the use of a vaccine formulation without the offending allergen for subsequent doses 
and also to avoid other products containing these allergens.  
Statement: Pre-immunization allergy tests (skin test, specific serum IgE) as screening do not reliably predict or 
exclude future allergic vaccine reactions and are not recommended.  
Testing serum IgE to microbial components is frequently unhelpful in preventing allergic vaccine reactions 
because the IgE response is part of the regular immune response and does not predict an allergic reaction to a 
vaccine (see section I B). Specific IgE tests are not commercially available for most microbial components. For 
some other constituents (e.g. ovalbumin and gelatin), the predictive capacity for reaction to vaccines is rather 
low. False positive tests may occur as many more individuals are allergic and sensitized to a given allergen than 
those reacting clinically on exposure to the minute amounts of this allergen encountered during immunization.  
Statement: After a vaccine reaction preferably specific IgE to egg/gelatin/latex/yeast should be analysed when 
suspected; otherwise skin test  is recommended. However, lack of data on the sensitivity and specificity of skin 
test to vaccines in different concentrations makes them unreliable in predicting or excluding future allergic 
vaccine reactions (48). More studies are needed to establish thresholds for the prediction of anaphylaxis to a 
vaccine.  
Skin testing can provide additional information about sensitization and the probability of a hapten/allergen 
being the culprit. This could help evaluate severe vaccine reactions. Skin testing should start with SPT 
(undiluted), a positive reaction being a sign of an allergic reaction. Skin prick testing sensitivity to vaccines itself 
is low. If negative, intradermal testing (0.02 mL) should follow (1:100 dilution, 1:10 dilution, see Figure 2). 
Undiluted intradermal testing is discouraged because of the high rate of irritant (non-relevant) reactions. False 
positive reactions may also occur at 1:10 dilution especially with influenza, MMR and varicella vaccines, and 
were even described for 1:100 dilutions in 5% of controls for DT and DTaP, and 15% for influenza (66). Thus, 
positive reactions should be regarded as indicative rather than confirmatory, and further studies are needed. 










This article is protected by copyright. All rights reserved. 
In non-immediate local reactions, contact dermatitis or subcutaneous nodules, type IV hypersensitivity to 
preservatives, aluminium, or antibiotics may be assessed by patch testing. Although patch testing is not 
essential for therapeutic decisions, it could help in choosing alternative vaccines if available. 
  
III B. Local aluminium reactions 
Statement: Aluminium-allergic persons can be vaccinated with aluminium-containing vaccines without 
inducing severe reactions, although new itching nodules may appear (67). 
Aluminium compounds, such as aluminium phosphate and aluminium hydroxide, are used as vaccine adjuvants 
and can induce type IV hypersensitivity (contact allergy) (68). Contact hypersensitivity to aluminium was 
demonstrated in 77% of the children with itching nodules and in 8% of the symptomless siblings who had 
received the same vaccines, i.e. not a specific test for symptoms. Subcutaneous nodules may develop and 
persist for months before they gradually disappear (67). Risk factors for aluminium sensitization at vaccination 
seem to be the dose of aluminium, the number of vaccinations, and the aluminium compound, where 
aluminium hydroxide seems more liable to induce sensitization than aluminium phosphate.  
In a prospective study of 4,758 children, 0.66% (n=38) developed an itching granuloma after Pentavac® (DTaP-
Hib-Polio vaccine). When Prevenar® (conjugated pneumococci vaccine) was added, the percentage was 1.2%, 
and most of them had positive patch tests to aluminium (69). Patch tests with aluminium chloride hexahydrate 
2% and elemental aluminium have been suggested, but some cases may be missed unless tested with 
aluminium chloride hexahydrate 10% (70). Patch tests should be read after three or four days and after one 
week (71). An itching granuloma and a positive epicutaneous test are illustrated in figure 4 and 5. 
III C. Identification of patients at risk and contraindications to immunization 
 
Currently available tools cannot predict most of the severe allergic reactions following immunization. Patients 
who manifested a severe allergic reaction following immunization are considered at high risk for the next 
immunization and merit special precautions (72) (see IV B).  
Patients who reacted clinically to an allergen contained in the vaccine are at increased risk of allergic vaccine 
reactions. Although specific sensitization can increase the risk of allergic reaction to vaccines, atopy in general 
does not seem an important risk factor (73). 
Statement: Atopy and family history of allergy or asthma are not per se contraindications for immunization.  
 
Few real contraindications for routine immunizations exist. Patients are often falsely labelled as allergic 
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severe (life-threatening) adverse events following immunization should not be re-immunized with the same 
vaccine before allergological investigations are completed. Most patients can be immunized safely (see 
introduction).  
 
Statement: Local reactions to antibiotics are not a contraindication for immunization. 
 
Previous localized delayed-type reactions to thiomersal, neomycin or aluminium are not considered absolute 
reasons for withholding vaccines because the risks of not being immunized outweigh problems caused by local 
reactions. 
Patients with mastocytosis, particularly children, are at increased risk of mast cell-mediated reactions after 
various triggers including routine vaccination. Therefore, we recommend administering vaccines in single 
injections, avoiding co-administrations, under medical supervision for at least 30 minutes (74). 
 
IV. Practical aspects 
As it is important to evaluate whether there is an evident risk of allergic reactions, patients should be asked 
whether they experienced allergic symptoms following previous vaccinations. Also, underlying uncontrolled 
diseases must be ruled out. 
Statement: Expertise and equipment for treating anaphylaxis should always be available when immunizing. 
All vaccinating units need to have adrenaline, antihistamine and oral steroids at hand and in most countries 
beta-2-inhalers. For patients at risk, also parenteral steroids, oxygen and a defibrillator should be available 
close to where the vaccinations are administered. 
 
IV A. Immunization of patients at increased risk  
Statement: A history of a previous allergic reaction to a vaccine or to one of its constituents should be 
ascertained before immunization.  
Identification of increased risks through clinical history is essential for risk minimization. Patients with a 
positive history should be investigated for type I hypersensitivity to the vaccine and its ingredients, and 
vaccination should be managed following specific recommendations for subjects allergic to vaccine 
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Statement: Immunization under standard conditions (standard vaccine, full dose, no mandatory observation 
time) is recommended for patients with:  
- Allergic sensitization but without a clinical reaction to an allergen contained in the vaccine;  
- Allergic disease not related to a vaccine; 
- Family history of allergy.  
 
Statement: If, based on a positive benefit/risk balance, an additional dose is needed after an anaphylactic 
vaccine reaction, a vaccine preparation without the offending ingredient should be preferred.  
 
Statement: Egg-allergic patients can be MMR-immunized under standard conditions. 
Data from clinical studies suggest that the small amount of residual egg protein in MMR vaccines represents an 
exceptionally uncommon risk for egg-allergic patients (75). 
Statement: Patients with manifest egg allergy who intend to be influenza-immunized should only be 
vaccinated with low egg (<0.12 µg/mL) vaccines:  
(A) Previous non-anaphylactic reactions to egg: can be influenza-vaccinated under standard conditions 
(B) Previous anaphylaxis to egg: single-dose vaccination with a personal staff experienced in recognizing and 
treating anaphylactic reactions under observation (minimum 1 hour). 
 
Gelatine-allergic patients could most often receive an alternative vaccine without gelatine as a stabilizer. 
Otherwise, SPT with the vaccine should be performed and, if positive, fractionated vaccine doses administered 
(17).  
 
IV B Fractionated immunization or graded desensitization. Management of 
allergic reactions to vaccines.  
Patients sensitized to a vaccine or its components with previous anaphylaxis to this vaccine should be 
revaccinated only if absolutely necessary. If at all possible, a vaccine without the offending allergen should be 
chosen. Where this is not possible, two pragmatic (not evidence-based) approaches have been used: 
Assuming that a smaller vaccine dose does less harm than a full dose, patients with negative skin tests to the 










This article is protected by copyright. All rights reserved. 
vaccination. Initially, 10% of the dose is given, followed 30 min later by the remaining 90% provided that no 
allergic reaction has occurred after the initial dose.  
As in rapid desensitization, immunization in graded doses may reduce the risk of anaphylaxis. Increasing 
vaccine doses are administered every 15-30 minutes provided that there are no signs of allergic reaction 
(0.05ml of 1:10 dilution, then 0.05ml, 0.1ml, 0.15ml, 0.2ml, of a 0.5ml full-strength vaccine) (17). Importantly, 
this protocol only leads to transient desensitization, and patients undergoing this protocol successfully must 
still be considered allergic to the vaccine. These vaccination approaches must only be used in a controlled 
setting where prompt treatment of anaphylaxis by experienced staff is available, see Figure 3.  
 
IV C. Delay of routine immunization 
Statement: Delay of routine immunizations is not recommended. Delay withholds protection from vaccine-
preventable disease, and there is no justifiable evidence that it would prevent allergic reactions or 
development of allergic disease.  
One study reported that delaying primary DTP immunization beyond 2 months of age was associated with a 
50% risk reduction of recorded asthma by age 7 years (76). This effect could not be replicated (77) and may 
have been reporting bias. A further study of children with ≥ 2-month delay in the 3rd DTP dose reported a 20% 
risk reduction in hay fever at school age (78). In contrast, a recent large Swedish study did not show any 
increased risk of requiring asthma medication whether the first DTaP vaccine was administered at 2 months or 
at 3 months of age (32). Studies on the effects of delaying other immunizations are lacking. The risk of vaccine-
preventable disease outweighs a doubtful risk reduction in allergic disease. 
 
V. Strategic aspects 
V A. Surveillance  
Statement: EAACI should make efforts to register severe vaccine adverse events.  
Strategies to monitor AEFI need to be developed, particularly those that may have an underlying allergic 
aetiology. Here, EAACI can play an important role by encouraging the sharing of best practice and insights 
gained within and between member countries, and through fostering common surveillance approaches to 
assess beneficial and adverse impacts of immunization strategies. Greater use of electronic health record 
systems is likely to be the key to such efforts in the future. 
Concerning paediatric patients, adverse reactions to vaccines are already the most common reactions reported 
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V B. Risk communication 
Public interest in the field of risk communication and vaccines is growing, fuelled by contemporary debate 
about perceived adverse events and easy access to information via the internet, which, however, increases the 
risk of misinformation. Although public confidence in vaccines is may be decreasing [79, 80], the public’s trust 
in health care workers remains well documented. Therefore, it is important to properly educate and train 
vaccine providers to maintain public acceptance of immunizations [81].  
The extensive scientific literature on risk communication includes several publications on immunization and 
allergy, but apart from advice on egg allergy [56], few studies on risk communication specifically address 
allergy in connection with immunization. The general literature on risk communication highlights the value of 
transparency, sensitivity and respect, with trust and confidence as essential elements [80, 82]. There is no 
reason for other strategies when communicating risks concerning immunizations and allergy. Denying or 
diminishing known risks is unethical and can lead to a higher risk perception among the target group [83].  
 
V C. Education and information for health professionals  
To communicate effectively with patients/carers and members of their teams, health care professionals need 
accurate, authoritative and accessible information on the potential benefits and risks of immunizations. It is 
unrealistic to expect busy professionals to read, digest and interpret the substantial body of epidemiological 
and health services research on this subject. They also need tools to communicate these benefits/risks in an 
open, non-coercive way to foster relationship-building and trust between health providers and patients/carers. 
As a respected professional body throughout Europe, EAACI can play an important leadership and coordinating 
role by ensuring the consistency of key messages being transmitted to health professionals throughout Europe 
and by eliciting information on professional concerns and hitherto unanswered questions. 
 
V D. Future vaccine development and use 
Vaccination stimulates different types of Th cells and IgE production. Immunological effects can be 
considerable, particularly when adjuvants are used. When trials of new vaccines or vaccine components are 
planned, aspects of clinical allergy and its immunological features should be integrated into research 
protocols. Also, both stabilizers and adjuvants in new vaccine compositions should be evaluated. New vaccines 
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V E. Research needs 
A validated test predicting clinical reactions following vaccination would be of major benefit. Such a study 
could examine whether graded desensitization has a role in these situations, and the results could be further 
studied, potentially through a network within EAACI. 
 
Aluminium gives local itchy granuloma from paediatric vaccinations in approximately 1% of cases. A change of 
adjuvant might be advisable.  
 
Although extensive scientific research has not concluded that vaccination promotes allergic diseases, new data 
from ongoing studies, and new environmental factors and vaccine constituents will require us to conduct 
retrospective and prospective studies in the future.  
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Figure 1: Contamination by culture media in the preparation of vaccines 
 
Figure 2: Diagnostic algorithm in case of suspected allergic reaction to vaccine or 
vaccine component 
 
Figure 3: Pre-immunization testing and immunization  
in patients who had a suspected previous allergic reaction to a vaccine 
 
Figure 4: Local reaction after vaccination at 3, 5 and 12 months of age with DTaP-
Hib-polio 
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Table 1. Abbreviations: 
AEFI adverse event following immunization 
BC Brighton Collaboration 
CDC Centers for Disease Control and Prevention 
D Diphtheria 
DTaP Diphtheria - Tetanus - Acellular Pertussis 
DTP Diphtheria - Tetanus - Pertussis 
EAACI  European Academy of Allergy and Clinical Immunology 
HBV Hepatitis B vaccine 
Hib Haemophilus Influenzae type b 
IIV  Trivalent and quadrivalent inactivated influenza vaccine 
IPV Inactivated polio vaccine 
RIV  Recombinant subunit influenza vaccine  
LAIV  Live attenuated trivalent and quadrivalent influenza vaccine 
MCT Mast Cell Tryptase 
MMR Measles - Mumps – Rubella 
OPV Oral Polio Vaccine 
P Pertussis 
PCV Pneumococcal conjugated vaccine 
T Tetanus 
TBE Tick-borne encephalitis 
TIV Trivalent inactivated influenza vaccine 
WAO World Allergy Organization 
WHO  World Health Organization 
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Table 4 Differentiation of anaphylaxis and vasovagal reaction.  
 
Possible symptoms Anaphylactic reaction Vasovagal reaction 
Onset from time of 
immunization 
Few minutes delay, 
typically within 30 minutes 
During or shortly after injection
Respiratory Wheezing, stridor Normal or hyperventilation 
Cardiovascular Tachycardia, hypotension Self-limited bradycardia, 
hypotension 
Skin  Flushing, itchy rash, 
angioedema, urticaria 
Pale, sweaty, cold, clammy 
Gastrointestinal Abdominal cramps Nausea, vomiting 
Neurological Loss of or altered
consciousness, little response 
to prone positioning 
Self-limited loss of 
consciousness, 
good response to prone 
positioning 
 





Table 5: Common, minor local vaccine reactions  
 
 
Vaccine Local adverse 
events (pain, 
swelling, redness) 
Measles/MR/MMR 1 of 20 (mild rash)
Pertussis (DTaP) 1 of 4* (redness or swelling)
Pneumococcal conjugate (PCV 13) 
Pneumococcal unconjugated 
1 of 3 (swelling) 
1 of 2 (redness or pain) 
Tdap 1 of 5 (redness or swelling) 
(3 of 4 pain) 
Varicella 1 of 5 (soreness or swelling) 
HPV (quadrivalent) 1 of 3 (redness or swelling)
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Figure 1: 
 
Contamination by culture media 
in the preparation of vaccines
 Human diploid cell (HDC) culture
Rabies
No ovalbumin
 Chicken fibroblast cell culture
Measles-mumps-rubella, TBE, rabies 
≤1ng per dose
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Skin prick test  




Intradermal test  
(vaccine) 
1 : 100 dilution 
If negative 
Intradermal test  
(vaccine) 
1 : 10 dilution  
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Figure 3: Pre-immunization testing and immunization  
in patients who had a suspected previous allergic reaction to a vaccine 
 
Allergic reaction to 
previous vaccine dose 
Skin test result Vaccine 
administration 
Precautions 
Local reaction Not needed Full dose No observation period 
Anaphylaxis, systemic 
reaction  
Negative Allergen avoidancex if 
possible, split dose 
60 minutes 
observation, IV line  
Anaphylaxis, systemic 
reaction 
Positive  Allergen avoidancex if 
possible, graded doses 
60 minutes 
observation, 
monitoring, IV line 
 
xAllergen avoidance does not mean no vaccination, but using an allergen-free vaccine or a low 

































luminium 2% in a 2-year-old child 
 
